Summarized by Masters of Longevity from Longevity Technology.
A short news piece previewing a preclinical study that examines combining a muscle-preserving biologic with GLP‑1 therapy to shift weight loss toward fat while assessing dosing potential and durability.
Key Takeaways
- Combining IBIO-610 with semaglutide shifted more weight loss toward fat and preserved lean mass in primates.
- A single intravenous dose of IBIO-610 produced a 97% reduction in serum active Activin E eight weeks after dosing.
- IBIO-610 showed a 33.2-day half-life in primates, supporting potential infrequent dosing in humans.
